November 12, 2024CorporateTerumo Blood and Cell Technologies Merges Therapeutics Units to Enhance Patient Care Across Treatment JourneyNew Global Therapy Innovations business unit, led by Veerle d’Haenens, aims to unify therapeutic apheresis and cell and gene therapy expertise to expand therapeutic possibilities
November 07, 2024FinancialNotice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2025 (FY2024) (PDF 85.27 KB)
Investors Japanese Financial Results for the Second Quarter of the Fiscal Year Ending 3/2025 Nov. 7, 2024 IR Library Audio Webcast Stock Quote Prime Market of TSE: Last Trade JPY Change JPY (%) Volume View Chart Top Management Message Hikaru Samejima Chief Executive Officer GS26: 5-Year Growth strategy 2022 - 2026 IR Library IR materials and various reports Terumo Report Integrated Report 2023 Sustainability Sustainability at the Terumo Group From Devices to Solutions Vision for the Next 10 Years Shareholders & Stock Information on shareholders meeting and stock What's New November 08, 2024 Audio webcast and Q&A regarding Financial Results for the Second Quarter of FYE 3/2025 November 07, 2024 Presentation regarding Financial Results for the Second Quarter of FYE 3/2025 November 07, 2024 Notice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2025 (FY2024) (PDF 85.27 KB) November 05, 2024 Notice Concerning Status of Acquisition of Own Shares (PDF 82.32 KB) October 02, 2024 Notice Concerning Status of Acquisition of Own Shares (PDF 82.32 KB) (Acquisition of the Company's own shares under articles of incorporation pursuant to the paragraph 2 of Article 165 of the Companies Act of Japan) View all Business Overview Introduction to the businesses operated by the Terumo Group /business Technology Introduction to Terumo's research and development activities and production system /technology
November 08, 2024 Audio webcast and Q&A regarding Financial Results for the Second Quarter of FYE 3/2025
November 07, 2024 Notice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2025 (FY2024) (PDF 85.27 KB)
October 02, 2024 Notice Concerning Status of Acquisition of Own Shares (PDF 82.32 KB) (Acquisition of the Company's own shares under articles of incorporation pursuant to the paragraph 2 of Article 165 of the Companies Act of Japan)
